What is happening, page-3144

I think capital management could be on their side. If they can develop the biochip to a functional prototype, there should be options for non-dilutive capital for full commercialization and then leverage off that for the quantum chip? Preserves good value for shareholders where many end up diluting value through multiple capital raises at rather large discounts. If they validate the biochip (perhaps through Spain), I think the development could progress quickly as there's plenty of existing data on manual (in lab) diagnostics which they need to transcribe to lab on chip -amazing then the possibilities?? Could be either much more rapid results and more functional use for remote diagnostics. Hope the base is in. GLTA